ПСИХИЧЕСКИЕ РАССТРОЙСТВА И СЕРДЕЧНО-СОСУДИСТЫЕ БОЛЕЗНИ: КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ БАЙКАЛЬСКОЙ И СИБИРСКОЙ ПСИХОСОМАТИЧЕСКИХ АССОЦИАЦИЙ

Члены рабочей группы подтвердили отсутствие финансовой поддержки и конфликта интересов.

1. World Health Organization. Mental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders. 2023. 152 с.

2. Байкальская психосоматическая ассоциация. Клинические рекомендации по психосоматической медицине. Иркутск. 2024. 35 с. URL: https:// therapy.irkutsk.ru/ispm/psomatic5.pdf.

3. Кардиоваскулярная профилактика 2022. Российские национальные рекомендации. Российский кардиологический журнал. 2023;28(5):5452.

4. Российское общество психиатров. Депрессивный эпизод, рекуррентное депрессивное расстройство. 2021. 88 с.

5. Российское общество психиатров. Генерализованное тревожное расстройство. 2021. 101 с.

6. Albus C, Waller C, Fritzsche K, Gunold H, et al. Significance of psychosocial factors in cardiology: update 2018: Position paper of the German Cardiac Society. Clin Res Cardiol. 2019;108(11):1175-1196.

7. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Major Depressive Disorder. Third Edition. Am J Psychiatry. 2010;167(suppl):1-152.

8. Colquhoun DM, Bunker SJ, Clarke DM, et al. Screening, referral and treatment for depression in patients with coronary heart disease. Med J Aust. 2013 May 20;198(9):483-4.

9. Frost JL, Rich RL, Robbins CW, et al. Depression Following Acute Coronary Syndrome Events: Screening and Treatment Guidelines from the AAFP. Am Fam Physician. 2019 Jun 15;99(12).

10. Ladwig K, Baghai T, Doyle F, et al. Mental health-related risk factors and interventions in patients with heart failure: a position paper endorsed by the European Association of Preventive Cardiology (EAPC). European Journal of Preventive Cardiology. 2022;29:1124–1141.

11. Lichtman JH, Froelicher ES, Blumenthal JA, et al. Depression as a Risk Factor for Poor Prognosis Among Patients With Acute Coronary Syndrome: Systematic Review and Recommendations. Circulation. 2014;129:1350–1369.

12. Lichtman JH, Bigger JT Jr, Blumenthal JA, et al. Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Psychiatric Association. Circulation. 2008 Oct 21;118(17):1768-75.

13. National Heart Foundation of Australia. Screening, referral and treatment for depression in patients with coronary heart disease. MJA. 2013; 198(9): 1-7.

14. Visseren F, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. 2021;34:3227-3337.

15. Vaccarino V, Badimon L, Bremner J, et al. Depression and coronary heart disease: 2018 position paper of the ESC working group on coronary pathophysiology and microcirculation. European Heart Journal. 2020;17:1687-1696.

16. The American Psychiatric Publishing Textbook of Psychosomatic Medicine: Psychiatric Care of the Medically Ill. Third Edition. Edited by James L. Levenson. 2019. 1410 p.

17. Лебедева Е.В., Нонка Т.Г., Репин А.Н., и др. Современная психокардиология. Томск, 2019. 160 с.

18. Собенников В.С., Белялов Ф.И. Соматизация и психосоматические расстройства. Иркутск: РИО ИГИУВа, 2010. 223 с.

19. Психосоматические расстройства. Руководство для практических врачей. Под ред. А.Б.Смулевича. 2-е изд. М, 2019. 496 с.

20. Белялов Ф.И. Психосоматика. 9-е изд. Москва: ГЭОТАР-Медиа, 2022. 400 c.

21. World Health Organization. Clinical descriptions and diagnostic requirements for ICD-11 mental, behavioural and neurodevelopmental disorders. 2024. 834 p.

22. МКБ-11. Глава 6. Психические и поведенческие расстройства и нарушения нейропсихического развития. Статистическая классификация. М, 2021. 432 с.

23. Stein D, Szatmari P, Gaebel W, et al. Mental, behavioral and neurodevelopmental disorders in the ICD-11: an international perspective on key changes and controversies. BMC Medicine. 2020;1:21.

24. Levis B, Benedetti A, Riehm K, et al. Probability of major depression diagnostic classification using semi-structured versus fully structured diagnostic interviews. The British Journal of Psychiatry. 2018;212:377-385.

25. Kwapong Y, Boakye E, Khan S, et al. Association of Depression and Poor Mental Health With Cardiovascular Disease and Suboptimal Cardiovascular Health Among Young Adults in the United States. Journal of the American Heart Association. 2023;3:e028332.

26. Bojanić I, Sund E, Sletvold H, et al. Prevalence trends of depression and anxiety symptoms in adults with cardiovascular diseases and diabetes 1995–2019: The HUNT studies, Norway. BMC Psychology. 2021;1:130.

27. Погосова Н.В., Бойцов С.А., Оганов Р.Г. и др. Клинико-эпидемиОлогическая программа изучения психосоциальных факторов риска в кардиологической практике у больных артериальной гипертонией и ишемической болезнью сердца (КОМЕТА): первые результаты российского многоцентрового исследования. Кардиология. 2018;58(9):47-58.

28. Karami N, Kazeminia M, Karami A, et al. Global prevalence of depression, anxiety, and stress in cardiac patients: A systematic review and meta-analysis. Journal of Affective Disorders. 2023;324:175-189.

29. Gaffey AE, Gathright EC, Fletcher LM, Goldstein CM. Screening for Psychological Distress and Risk of Cardiovascular Disease and Related Mortality: A Systematized Review, Meta-analysis, and Case for Prevention. J Cardiopulm Rehabil Prev. 2022 Nov 1;42(6):404-415.

30. Seldenrijk A, Vogelzangs N, Batelaan NM, et al. Depression, anxiety and 6-year risk of cardiovascular disease. Journal of Psychosomatic Research. 2015;78(2):123-129.

31. Nakamura S, Kato K, Yoshida A, et al. Prognostic Value of Depression, Anxiety, and Anger in Hospitalized Cardiovascular Disease Patients for Predicting Adverse Cardiac Outcomes. The American journal of cardiology. 2013;111[10]:1432-1436.

32. Fan AZ, Strine TW, Jiles R, et al. Psychological distress, use of rehabilitation services, and disability status among noninstitutionalized US adults aged 35 years and older, who have cardiovascular conditions, 2007. Int J Public Health. 2009;54 Suppl 1:100-5.

33. Charlson FJ, Moran AE, Freedman G, et al. The contribution of major depression to the global burden of ischemic heart disease: a comparative risk assessment. BMC Med. 2013; 11:250. 10.1186/1741-7015-11-250

34. Bekelman DB, Havranek EP, Becker DM, et al. Symptoms, depression, and quality of life in patients with heart failure. J Card Fail. 2007;13(8):643-648.

35. Gravely-Witte S, De Gucht V, Heiser W, et al. The impact of angina and cardiac history on health-related quality of life and depression in coronary heart disease patients. Chronic Illn. 2007;3(1):66-76.

36. Huang W, Aune D, Ferrari G, et al. Psychological Distress and All-Cause, Cardiovascular Disease, Cancer Mortality Among Adults with and without Diabetes. Clin Epidemiol. 2021;13:555-565.

37. Meier SM, Mattheisen M, Mors O, et al. Increased mortality among people with anxiety disorders: total population study. Br J Psychiatry. 2016;209(3):216-21.

38. Zhang Z, Jackson SL, Gillespie C, et al. Depressive Symptoms and Mortality Among US Adults. JAMA Netw Open. 2023;6(10):e2337011.

39. Péquignot R, Dufouil C, Pérès K, et al. Depression Increases the Risk of Death Independently From Vascular Events in Elderly Individuals: The Three-City Study. Journal of the American Geriatrics Society. 2019;3:546-552.

40. Shen R, Zhao N, Wang J, et al. Association between level of depression and coronary heart disease, stroke risk and all-cause and cardiovascular mortality: Data from the 2005–2018 National Health and Nutrition Examination Survey. Frontiers in Cardiovascular Medicine. 2022;9.

41. Tian F, Shen Q, Hu Y, et al. Association of stress-related disorders with subsequent risk of all-cause and cause-specific mortality: A population-based and sibling-controlled cohort study. The Lancet Regional Health – Europe. 2022;18:100402.

42. Mourad G, Jaarsma T, Hallert C, Strömberg A. Depressive symptoms and healthcare utilization in patients with noncardiac chest pain compared to patients with ischemic heart disease. Heart Lung. 2012 Sep-Oct;41(5):446-55.

43. Mourad G, Lundgren J, Andersson G, Johansson P. Healthcare use in patients with cardiovascular disease and depressive symptoms - The impact of a nurse-led internet-delivered cognitive behavioural therapy program. A secondary analysis of a RCT. Internet Interv. 2023 Dec 5;35:100696.

44. Ni J, Yan Y, Du W, et al. Depressive symptoms, alone or together with physical comorbidity, are predictive of healthcare use and spending in older adults. Journal of Psychosomatic Research. 2023;174:111482.

45. Stephenson J, Grabner M, Faries D, et al. The impact of anxiety on Healthcare Utilization and costs among respondents from the Co-Morbidities and Symptoms of depression (CODE) study. Value in Health. 2015;3:A119.

46. Horenstein A, Heimberg RG. Anxiety disorders and healthcare utilization: A systematic review. Clin Psychol Rev. 2020;81:101894.

47. Eisele M, Harder M, Rakebrandt A, et al. Association of depression and anxiety with adherence in primary care patients with heart failure—cross-sectional results of the observational RECODE-HF cohort study. Family Practice. 2020;5:695-702.

48. Crawshaw J, Auyeung V, Norton S, Weinman J. Identifying psychosocial predictors of medication non-adherence following acute coronary syndrome: A systematic review and meta-analysis. Journal of Psychosomatic Research. 2016;90:10-32.

49. Dempe C, Jünger J, Hoppe S, et al. Association of anxious and depressive symptoms with medication nonadherence in patients with stable coronary artery disease. Journal of Psychosomatic Research. 2013;74(2):122-127.

50. Rasmussen A, Wiggers H, Jensen M, et al. Patient-reported outcomes and medication adherence in patients with heart failure. European Heart Journal - Cardiovascular Pharmacotherapy. 2021;4:287-295.

51. Curth N, Hjorthøj C, Brinck-Claussen U, et al. The effects of collaborative care versus consultation liaison for anxiety disorders and depression in Denmark: two randomised controlled trials. The British Journal of Psychiatry. 2023;223:430-437.

52. Archer J, Bower P, Gilbody S, et al. Collaborative care for depression and anxiety problems. Cochrane Database Syst Rev. 2012 Oct 17;10:CD006525.

53. Sighinolfi C, Nespeca C, Menchetti M, et al. Collaborative care for depression in European countries: a systematic review and meta-analysis. J Psychosom Res. 2014;77(4):247-63.

54. Лебедева Е.В., Репин А.Н., Счастный Е.Д. и др. Методическое пособие по организации работы междисциплинарной команды при реабилитации пациентов с хронической ишемической болезнью сердца и депрессивными расстройствами. – Томск. 2012. 66 с.

55. Silverman JJ, Galanter M, Jackson-Triche M, et al. The American Psychiatric Association Practice Guidelines for the Psychiatric Evaluation of Adults. Am J Psych. 2015;172(8):798-802.

56. Correll CU, Galling B, Pawar A, et al. Comparison of Early Intervention Services vs Treatment as Usual for Early-Phase Psychosis: A Systematic Review, Meta-analysis, and Meta-regression. JAMA Psychiatry. 2018 Jun 1;75(6):555-565.

57. Albert N, Melau M, Jensen H, et al. Five years of specialised early intervention versus two years of specialised early intervention followed by three years of standard treatment for patients with a first episode psychosis: randomised, superiority, parallel group trial in Denmark (OPUS II). BMJ. 2017 Jan 12;356:i6681.

58. Olfson M, Blanco C, Marcus SC. Treatment of Adult Depression in the United States. JAMA Intern Med. 2016;176(10):1482-1491.

59. Linde K, Kriston L, Rücker G, et al. Efficacy and Acceptability of Pharmacological Treatments for Depressive Disorders in Primary Care: Systematic Review and Network Meta-Analysis. The Annals of Family Medicine. 2015;13(1):69-79.

60. Weisberg RB, Dyck I, Culpepper L, et al. Psychiatric Treatment in Primary Care Patients With Anxiety Disorders: A Comparison of Care Received From Primary Care Providers and Psychiatrists. Am J Psychiatry 2007;164:276-82.

61. Simon GE, Von Korff M, Rutter CM, Peterson DA. Treatment Process and Outcomes for Managed Care Patients Receiving New Antidepressant Prescriptions From Psychiatrists and Primary Care Physicians. Arch Gen Psychiatry. 2001;58:395-401.

62. Trautmann S, Beesdo-Baum K. The Treatment of Depression in Primary Care. Dtsch Arztebl Int. 2017 Oct 27;114(43):721-728.

63. Приказ Министерства здравоохранения Российской Федерации от 26.12.2023 N720н "Об утверждении Перечня медицинских противопоказаний для осуществления отдельных видов деятельности вследствие психического расстройства". https://webmed.irkutsk.ru/doc/order/mz720.pdf

64. Jha M, Qamar A, Vaduganathan M, et al. Screening and Management of Depression in Patients With Cardiovascular Disease. Journal of the American College of Cardiology. 2019;14:1827-1845.

65. US Preventive Services Task Force. Screening for Depression and Suicide Risk in Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2023;329(23):2057–2067.

66. US Preventive Services Task Force. Screening for Anxiety Disorders in Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2023;329(24):2163–2170.

67. Золотарева А.А. Адаптация русскоязычной версии шкалы генерализованного тревожного расстройства (Generalized Anxiety Disorder-7). Консультативная психология и психотерапия. 2023;31:31–46.

68. Погосова Н.В., Довженко Т.В., Бабин А.Г., и др. Русскоязычная версия опросников PHQ-2 и 9: чувствительность и специфичность при выявлении депрессии у пациентов общемедицинской амбулаторной практики. Кардиоваскулярная терапия и профилактика. 2014;13(3):18-24. https://doi.org/10.15829/1728-8800-2014-3-18-24

69. Морозова М.А., Потанин С.С., Бениашвили А.Г. и др. Валидация русскоязычной версии Госпитальной шкалы тревоги и депрессии в общей популяции. Профилактическая медицина. 2023;26(4):7‑14.

70. Белялов Ф.И. Прогнозирование и шкалы в медицине. 4-е изд. Москва: ГЭОТАР-Медиа, 2023. 416 с.

71. Wu Y, Levis B, Sun Y, et al. Accuracy of the Hospital Anxiety and Depression Scale Depression subscale (HADS-D) to screen for major depression: systematic review and individual participant data meta-analysis. BMJ. 2021 May 10;373:n972. doi: 10.1136/bmj.n972.

72. Levis B, Benedetti A, Thombs BD; DEPRESsion Screening Data (DEPRESSD) Collaboration. Accuracy of Patient Health Questionnaire-9 (PHQ-9) for screening to detect major depression: individual participant data meta-analysis. BMJ. 2019 Apr 9;365:l1476. doi: 10.1136/bmj.l1476. Erratum in: BMJ. 2019 Apr 12;365:l1781.

73. Manea L, Gilbody S, McMillan D. A diagnostic meta-analysis of the Patient Health Questionnaire-9 (PHQ-9) algorithm scoring method as a screen for depression. Gen Hosp Psychiatry. 2015;37(1):67-75.

74. Christensen A, Dixon J, Juel K, et al. Psychometric properties of the Danish Hospital Anxiety and Depression Scale in patients with cardiac disease: results from the DenHeart survey. Health and Quality of Life Outcomes. 2020;1:9.

75. Thombs BD, Ziegelstein RC, Roseman M, et al. There are no randomized controlled trials that support the United States Preventive Services Task Force guideline on screening for depression in primary care: a systematic review. BMC Medicine. 2014;12:13.

76. Romera I, Montejo Á, Aragonés E, et al. Systematic depression screening in high-risk patients attending primary care: a pragmatic cluster-randomized trial. BMC Psychiatry. 2013;1:83.

77. O'Connor EA, Henninger ML, Perdue LA, et al. Anxiety Screening: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2023 Jun 27;329(24):2171-2184.

78. Moore M, Ali S, Stuart B, et al. Depression management in primary care: an observational study of management changes related to PHQ-9 score for depression monitoring. Br J Gen Pract. 2012;62(599):e451-7.

79. Toussaint A, Hüsing P, Gumz A, Wingenfeld K, Härter M, Schramm E, Löwe B. Sensitivity to change and minimal clinically important difference of the 7-item Generalized Anxiety Disorder Questionnaire (GAD-7). J Affect Disord. 2020 Mar 15;265:395-401. doi: 10.1016/j.jad.2020.01.032.

80. Murphy B, Le Grande M, Alvarenga M, et al. Anxiety and Depression After a Cardiac Event: Prevalence and Predictors. Frontiers in Psychology. 2020;10.

81. ICSI. Major Depression in Adults in Primary Care. 17th edition. 2016. 131 p.

82. Screening adults for depression in primary care: A position statement of the American College of Preventive Medicine. J Fam Pract. 2009;58(10):535-8.

83. Plummer F, Manea L, Trepel D, McMillan D. Screening for anxiety disorders with the GAD-7 and GAD-2: a systematic review and diagnostic metaanalysis. Gen Hosp Psychiatry. 2016;39:24–31.

84. Adzrago D, Walker T, Williams F, et al. Reliability and validity of the Patient Health Questionnaire-4 scale and its subscales of depression and anxiety among US adults based on nativity. BMC Psychiatry. 2024;1:213.

85. Reavell J, Hopkinson M, Clarkesmith D, Lane DA. Effectiveness of Cognitive Behavioral Therapy for Depression and Anxiety in Patients With Cardiovascular Disease: A Systematic Review and Meta-Analysis. Psychosom Med. 2018;80(8):742-753.

86. Holdgaard A, Eckhardt-Hansen C, Lassen C, et al. Cognitive-behavioural therapy reduces psychological distress in younger patients with cardiac disease: a randomized trial. European Heart Journal. 2023;11:986-996.

87. El Baou C, Desai R, Cooper C, et al. Psychological therapies for depression and cardiovascular risk: evidence from national healthcare records in England. European Heart Journal. 2023;18:1650-1662.

88. Cuijpers P, Miguel C, Harrer M, et al. Cognitive behavior therapy vs. control conditions, other psychotherapies, pharmacotherapies and combined treatment for depression: a comprehensive meta-analysis including 409 trials with 52,702 patients. World Psychiatry. 2023;22(1):105-115.

89. Ding N, Sang Y, Chen J, et al. Cigarette Smoking, Smoking Cessation, and Long-Term Risk of 3 Major Atherosclerotic Diseases. Journal of the American College of Cardiology. 2019;4:498-507.

90. Wu AD, Lindson N, Hartmann-Boyce J, et al. Smoking cessation for secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews 2022, Issue 8. Art. No.: CD014936.

91. Taylor GMJ, Lindson N, Farley A, et al. Smoking cessation for improving mental health. Cochrane Database of Systematic Reviews 2021, Issue 3. Art. No.: CD013522.

92. Benowitz NL, Pipe A, West R, et al. Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers. A Randomized Clinical Trial. JAMA Intern Med. 2018;178(5):622–631.

93. Auer R, Schoeni A, Humair J, et al. Electronic Nicotine-Delivery Systems for Smoking Cessation. N Engl J Med. 2024;7:601-610.

94. Lindson N, Butler AR, McRobbie H, et al. Electronic cigarettes for smoking cessation. Cochrane Database of Systematic Reviews 2024, Issue 1. Art. No.: CD010216.

95. Livingstone-Banks J, Fanshawe TR, Thomas KH, et al. Nicotine receptor partial agonists for smoking cessation. Cochrane Database of Systematic Reviews 2023, Issue 6. Art. No.: CD006103.

96. Rigotti NA, Benowitz NL, Prochaska J, et al. Cytisinicline for Smoking Cessation: A Randomized Clinical Trial. JAMA. 2023;330(2):152–160.

97. Krittanawong C, Isath A, Rosenson R, et al. Alcohol Consumption and Cardiovascular Health. The American Journal of Medicine. 2022;10:1213-1230.e3.

98. Biddinger KJ, Emdin CA, Haas ME, et al. Association of Habitual Alcohol Intake With Risk of Cardiovascular Disease. JAMA Netw Open. 2022;5(3):e223849.

99. Millwood I, Walters R, Mei X, et al. Conventional and genetic evidence on alcohol and vascular disease aetiology: a prospective study of 500 000 men and women in China. The Lancet. 2019;10183:1831-1842.

100. Holmes MV, Dale CE, Zuccolo L, et al. Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant data. BMJ. 2014 Jul 10;349:g4164.

101. Jayakody K, Gunadasa S, Hosker C. Exercise for anxiety disorders: systematic review. Br J Sports Med. 2014;48(3):187-96.

102. Hallgren M, Nguyen T, Herring M, et al. Associations of physical activity with anxiety symptoms and disorders: Findings from the Swedish National March Cohort. General Hospital Psychiatry. 2019;58:45-50.

103. Yu Q, Wong KK, Lei OK, et al. Comparative Effectiveness of Multiple Exercise Interventions in the Treatment of Mental Health Disorders: A Systematic Review and Network Meta-Analysis. Sports Med Open. 2022 Oct 29;8(1):135.

104. Cooney GM, Dwan K, Greig CA, et al. Exercise for depression. Cochrane Database Syst Rev. 2013;(9):CD004366.

105. Gordon BR, McDowell CP, Hallgren M, et al. Association of Efficacy of Resistance Exercise Training With Depressive Symptoms. Meta-analysis and Meta-regression Analysis of Randomized Clinical Trials. JAMA Psychiatry. 2018;75(6):566–576.

106. Carmin C, Ownby R, Fontanella C, et al. Impact of Mental Health Treatment on Outcomes in Patients With Heart Failure and Ischemic Heart Disease. Journal of the American Heart Association. 2024;0:e031117.

107. van Dis EAM, van Veen SC, Hagenaars MA, et al. Long-term Outcomes of Cognitive Behavioral Therapy for Anxiety-Related Disorders: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2020;77(3):265–273.

108. Papola D, Ostuzzi G, Tedeschi F, et al. Comparative efficacy and acceptability of psychotherapies for panic disorder with or without agoraphobia: systematic review and network meta-analysis of randomised controlled trials. The British Journal of Psychiatry. 2022;221:507-519.

109. Papola D, Miguel C, Mazzaglia M, et al. Psychotherapies for Generalized Anxiety Disorder in Adults: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials. JAMA Psychiatry. 2024;81(3):250–259.

110. Plessen CY, Karyotaki E, Miguel C, et al. Exploring the efficacy of psychotherapies for depression: a multiverse meta-analysis. BMJ Ment Health. 2023;26(1):e300626.

111. Kolovos S, Kleiboer A, Cuijpers P. Effect of psychotherapy for depression on quality of life: meta-analysis. The British Journal of Psychiatry. 2016;209(6):460.

112. Hofmann SG, Wu JQ, Boettcher H. Effect of cognitive-behavioral therapy for anxiety disorders on quality of life: a meta-analysis. J Consult Clin Psychol. 2014;82(3):375-91.

113. Karyotaki E, Efthimiou O, Miguel C, et al. Internet-Based Cognitive Behavioral Therapy for Depression: A Systematic Review and Individual Patient Data Network Meta-analysis. JAMA Psychiatry. 2021;78(4):361–371.

114. Hedman-Lagerlöf E, Carlbring P, Svärdman F, et al. Therapist-supported Internet-based cognitive behaviour therapy yields similar effects as face-to-face therapy for psychiatric and somatic disorders: an updated systematic review and meta-analysis. World Psychiatry. 2023;2:305-314.

115. Ricci C, Wood A, Muller D, et al. Alcohol intake in relation to non-fatal and fatal coronary heart disease and stroke: EPIC-CVD case-cohort study. BMJ. 2018;361:k934.

116. Millwood I, Walters R, Mei X, et al. Conventional and genetic evidence on alcohol and vascular disease aetiology: a prospective study of 500 000 men and women in China. The Lancet. 2019;10183:1831-1842.

117. Pearce M, Garcia L, Abbas A, et al. Association Between Physical Activity and Risk of Depression: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2022;79(6):550–559.

118. Jones ME, Campbell G, Patel D, et al. Risk of Mortality (including Sudden Cardiac Death) and Major Cardiovascular Events in Users of Olanzapine and Other Antipsychotics. Cardiovasc Psychiatry Neurol. 2013;2013:647476.

119. Salvo F, Pariente A, Shakir S, et al. Sudden cardiac and sudden unexpected death related to antipsychotics: A meta-analysis of observational studies.Clin Pharmacol Ther. 2016;99(3):306-14.

120. Weeke P, Jensen A, Folke F, et al. Antipsychotics and associated risk of out-of-hospital cardiac arrest. Clin Pharmacol Ther. 2014;96(4):490-7.

121. Piña I, Di Palo K, Ventura H, et al. Psychopharmacology and Cardiovascular Disease. Journal of the American College of Cardiology. 2018;20:2346-2359.

122. Белялов Ф.И. Лечение болезней в условиях коморбидности. 12-е изд. Москва: ГЭОТАР-Медиа,

123. Fanoe S, Kristensen D, Fink-Jensen A, et al. Risk of arrhythmia induced by psychotropic medications: a proposal for clinical management. European Heart Journal 2014;35:1306-1315.

124. Beach SR, Celano CM, Sugrue AM, et al. QT Prolongation, Torsades de Pointes, and Psychotropic Medications: A 5-Year Update. Psychosomatics. 2018;59(2):105-122.

125. Castro VM, Clements CC, Murphy SN, et al. QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ 2013;346.

126. Kasper S, Gastpar M, Muller WE, et al. Lavender oil preparation Silexan is effective in generalized anxiety disorder - a randomized, double-blind comparison to placebo and paroxetine. Int J Neuropsychopharmacol. 2014;17(6):859-69.

127. Donelli D, Antonelli M, Bellinazzi C, et al. Effects of lavender on anxiety: A systematic review and meta-analysis. Phytomedicine. 2019;65:153099.

128. Zhao X, Zhang H, Wu Y, Yu C. The efficacy and safety of St. John's wort extract in depression therapy compared to SSRIs in adults: A meta-analysis of randomized clinical trials. Adv Clin Exp Med. 2023;32(2):151-161.

129. Cui YH, Zheng Y. A meta-analysis on the efficacy and safety of St John's wort extract in depression therapy in comparison with selective serotonin reuptake inhibitors in adults. Neuropsychiatr Dis Treat. 2016;12:1715-23.

130. de Vries Y, Roest A, Bos E, et al. Predicting antidepressant response by monitoring early improvement of individual symptoms of depression: individual patient data meta-analysis. The British Journal of Psychiatry. 2019;214:4-10.

131. Baldwin DS, Stein DJ, Dolberg OT, Bandelow B. How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database. Hum Psychopharmacol. 2009;24(4):269-75.

132. Cleare A, Pariante CM, Young AH, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2015;29(5):459-525.

133. Nochaiwong S, Ruengorn C, Awiphan R, et al. Use of serotonin reuptake inhibitor antidepressants and the risk of bleeding complications in patients on anticoagulant or antiplatelet agents: a systematic review and meta-analysis. Ann Med. 2022;54(1):80-97.

134. Khanassov V, Hu J, Reeves D, van Marwijk H. Selective serotonin reuptake inhibitor and selective serotonin and norepinephrine reuptake inhibitor use and risk of fractures in adults: A systematic review and meta-analysis. Int J Geriatr Psychiatry. 2018;33(12):1688-1708.

135. Rahman AA, Platt RW, Beradid S, et al. Concomitant Use of Selective Serotonin Reuptake Inhibitors With Oral Anticoagulants and Risk of Major Bleeding. JAMA Netw Open. 2024;7(3):e243208.

136. Gandhi S, Shariff SZ, Al-Jaishi A, et al. Second-Generation Antidepressants and Hyponatremia Risk: Population-Based Cohort Study of Older Adults. Am J Kidn Dis. 2016;69(1):87-96.

137. Viramontes TS, Truong H, Linnebur SA, et al. Antidepressant-Induced Hyponatremia in Older Adults. Consult Pharm. 2016;31(3):139-50.

138. De Picker L, Van Den Eede F, Dumont G, et al. Antidepressants and the Risk of Hyponatremia: A Class-by-Class Review of Literature. Psychosomatics. 2014;55:536-547.

139. Ojero-Senard A, Benevent J, Bondon-Guitton E, et al. A comparative study of QT prolongation with serotonin reuptake inhibitors. Psychopharmacology (Berl). 2017;234(20):3075-3081.

140. Funk KA, Bostwick JR. A comparison of the risk of QT prolongation among SSRIs. Ann Pharmacother. 2013;47(10):1330-41.

141. Beach SR, Kostis WJ, Celano CM, et al. Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation. J Clin Psychiatry. 2014;75(5):e441-9.

142. Van Leeuwen E, Driel ML, Horowitz MA, et al. Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults. Cochrane Database of Systematic Reviews 2021, Issue 4. Art. No.: CD013495.

143. Almuwaqqat Z, Jokhadar M, Norby FL, et al. Association of Antidepressant Medication Type With the Incidence of Cardiovascular Disease in the ARIC Study. J Am Heart Assoc. 2019 Jun 4;8(11):e012503.

144. Coupland C, Hill T, Morriss R, et al. Antidepressant use and risk of cardiovascular outcomes in people aged 20 to 64: cohort study using primary care database. BMJ. 2016;352.

145. Mease PJ, Zimetbaum PJ, Duh, et al. Epidemiologic Evaluation of Cardiovascular Risk in Patients Receiving Milnacipran, Venlafaxine, or Amitriptyline: Evidence from French Health Data. Ann Pharmacother. 2011;45(2):179-88.

146. Maslej MM, Bolker BM, Russell MJ, et al. The Mortality and Myocardial Effects of Antidepressants Are Moderated by Preexisting Cardiovascular Disease: A Meta-Analysis. Psychotherapy and Psychosomatics. 2017;86(5):268-282.

147. NICE. Generalised anxiety disorder and panic disorder in adults: management. January 2020. 43 p.

148. de las Cuevas C, Sanz E, de la Fuente J. Benzodiazepines: more "behavioural" addiction than dependence. Psychopharmacology (Berl). 2003;167(3):297-303.

149. Donnelly K, Bracchi R, Hewitt J, et al. Benzodiazepines, Z-drugs and the risk of hip fracture: A systematic review and meta-analysis. PLoS One. 2017 Apr 27;12(4):e0174730.

150. Poly T, Islam M, Yang H, et al. Association between benzodiazepines use and risk of hip fracture in the elderly people: A meta-analysis of observational studies. Joint Bone Spine. 2020;3:241-249.

151. Kim JH, Song YK, Jang HY, et al. Major Adverse Cardiovascular Events in Antidepressant Users Within Patients With Ischemic Heart Diseases: A Nationwide Cohort Study. J Clin Psychopharmacol. 2020 Sep/Oct;40(5):475-481.

152. Andersson N, Wohlfahrt J, Feenstra B, et al. Cumulative Incidence of Thiazide-Induced Hyponatremia. Ann Intern Med. 2024;1:1-11.

153. Jang HY, Kim JH, Song YK, et al. Antidepressant Use and the Risk of Major Adverse Cardiovascular Events in Patients Without Known Cardiovascular Disease: A Retrospective Cohort Study. Front Pharmacol. 2020 Dec 10;11:594474.

154. Al Dawsari A, Bushell TJ, Abutheraa N, et al. Use of sedative-hypnotic medications and risk of dementia: A systematic review and meta-analysis. Br J Clin Pharmacol. 2022;88(4):1567-1589.

155. Stott J, Saunders R, Desai R, et al. Associations between psychological intervention for anxiety disorders and risk of dementia: a prospective cohort study using national health-care records data in England. The Lancet Healthy Longevity. 2023;1:e12-e22.

156. Osler M, Jorgensen M. Associations of Benzodiazepines, Z-Drugs, and Other Anxiolytics With Subsequent Dementia in Patients With Affective Disorders: A Nationwide Cohort and Nested Case-Control Study. AJP. 2020;6:497-505.

157. Ray WA, Stein CM, Murray KT, et al. Association of Antipsychotic Treatment With Risk of Unexpected Death Among Children and Youths. JAMA Psychiatry. 2019;76(2):162–171.

158. Salvo F, Pariente A, Shakir S, et al. Sudden cardiac and sudden unexpected death related to antipsychotics: A meta-analysis of observational studies.Clin Pharmacol Ther. 2016;99(3):306-14.

159. Suvisaari J, Partti K, Perala J, et al. Mortality and Its Determinants in People With Psychotic Disorder. Psychosom Med 2013;75(1):60-7.

160. Hasnain M, Vieweg WV. QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review. CNS Drugs. 2014;28(10):887-920.

161. Huang K-L, Fang C-J, Hsu C-C, et al. Myocardial infarction risk and antipsychotics use revisited: a meta-analysis of 10 observational studies. Journal of Psychopharmacology. 2017;31(12):1544-1555.

162. Yu ZH, Jiang HY, Shao L, et al. Use of antipsychotics and risk of myocardial infarction: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016;82(3):624-32.

163. Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multiepisode schizophrenia: a systematic review and network meta-analysis. The Lancet. 2019;10202:939-951.

164. Pillinger T, McCutcheon R, Vano L, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. The Lancet Psychiatry. 2020;1:64-77.

165. NHS Foundation. Guidance on the Use of Antipsychotics. 2018. 60 p.

166. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Third edition. 2021. 299 p.

167. Российское общество психиатров. Паническое расстройство. 2021. 113 с.

168. Olariu E, Forero CG, Castro-Rodriguez JI, et al. Detection of anxiety disorders in primary care: a meta-analysis of assisted and unassisted diagnoses. Depress Anxiety. 2015;32(7):471-84.

169. Bandelow B, Reitt M, Röver C, et al. Efficacy of treatments for anxiety disorders: a meta-analysis. Int Clin Psychopharmacol. 2015;30(4):183-92.

170. Carpenter JK, Andrews LA, Witcraft SM, et al. Cognitive behavioral therapy for anxiety and related disorders: A meta-analysis of randomized placebo-controlled trials. Depress Anxiety. 2018;35(6):502-514.

171. Furukawa TA, Watanabe N, Churchill R. Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia. The Cochrane Database of Systematic Reviews 2007 Issue 1.

172. Parker E, Banfield M, Fassnacht D, et al. Contemporary treatment of anxiety in primary care: a systematic review and meta-analysis of outcomes in countries with universal healthcare. BMC Family Practice. 2021;1:92.

173. Bandelow B, Werner A, Kopp I, et al. The German Guidelines for the treatment of anxiety disorders: first revision. European Archives of Psychiatry and Clinical Neuroscience. 2022;4:571-582.

174. Christensen A, Dixon J, Juel K, et al. Psychometric properties of the Danish Hospital Anxiety and Depression Scale in patients with cardiac disease: results from the DenHeart survey. Health and Quality of Life Outcomes. 2020;1:9.

175. Bolgeo T, Di Matteo R, Simonelli N, et al. Psychometric properties and measurement invariance of the 7-item General Anxiety Disorder scale (GAD-7) in an Italian coronary heart disease population. J Affect Disord. 2023 Aug 1;334:213-219.

176. Guaiana G, Meader N, Barbui C, et al. Pharmacological treatments in panic disorder in adults: a network meta-analysis. Cochrane Database of Systematic Reviews 2023, Issue 11. Art. No.: CD012729.

177. Chawla N, Anothaisintawee T, Charoenrungrueangchai K, et al. Drug treatment for panic disorder with or without agoraphobia: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2022;376:e066084.

178. Carl E, Witcraft SM, Kauffman BY, et al. Psychological and pharmacological treatments for generalized anxiety disorder (GAD): a meta-analysis of randomized controlled trials. Cogn Behav Ther. 2020;49(1):1-21.

179. Slee A, Nazareth I, Bondaronek P, et al. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. The Lancet. 2019;10173:768-777.

180. Generoso MB, Trevizol AP, Kasper S, et al. Pregabalin for generalized anxiety disorder: an updated systematic review and meta-analysis. Int Clin Psychopharmacol. 2017;32(1):49-55.

181. Stubbs B, Vancampfort D, Rosenbaum S, et al. An examination of the anxiolytic effects of exercise for people with anxiety and stress-related disorders: A meta-analysis. Psychiatry Res. 2017;249:102-108.

182. Rebar AL, Stanton R, Geard D, et al. A meta-meta-analysis of the effect of physical activity on depression and anxiety in non-clinical adult populations. Health Psychol Rev. 2015;9(3):366-78.

183. Ramos-Sanchez CP, Schuch FB, Seedat S, et al. The anxiolytic effects of exercise for people with anxiety and related disorders: An update of the available meta-analytic evidence. Psychiatry Res. 2021;302:114046.

184. Donovan MR, Glue P, Kolluri S, Emir B. Comparative efficacy of antidepressants in preventing relapse in anxiety disorders - a meta-analysis. J Affect Disord. 2010;123(1-3):9-16.

185. Batelaan NM, et al. Risk of relapse after antidepressant discontinuation in anxiety disorders, obsessive-compulsive disorder, and post-traumatic stress disorder: systematic review and meta-analysis of relapse prevention trials. BMJ. 2017;358.

186. Perna G, Alciati A, Riva A, et al. Long-Term Pharmacological Treatments of Anxiety Disorders: An Updated Systematic Review. Curr Psychiatry Rep. 2016;18(3):23.

187. Nelson H, Cantor A, Pappas M, et al. Screening for Anxiety in Adolescent and Adult Women. Annals of Internal Medicine. 2020;1:29-41.

188. Guaiana G, Barbui C, Cipriani A. Hydroxyzine for generalised anxiety disorder. Cochrane Database of Systematic Reviews 2010, Issue 12.

189. Breilmann J, Girlanda F, Guaiana G, et al. Benzodiazepines versus placebo for panic disorder in adults. Cochrane Database of Systematic Reviews 2019, Issue 3. Art. No.: CD010677.

190. Guerlais M, Grall-Bronnec M, Feuillet F, et al. Dependence on prescription benzodiazepines and Z-drugs among young to middle-aged patients in France. Subst Use Misuse. 2015;50(3):320-7.

191. Martin JL, Sainz-Pardo M, Furukawa TA, et al. Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials. J Psychopharmacol. 2007;21(7):774-82.

192. Shinfuku M, Kishimoto T, Uchida H, et al. Effectiveness and safety of long-term benzodiazepine use in anxiety disorders: a systematic review and meta-analysis. Int Clin Psychopharmacol. 2019;34(5):211-221. van Dis EAM, van Veen SC, Hagenaars MA, et al. Long-term Outcomes of Cognitive Behavioral Therapy for Anxiety-Related Disorders: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2020;77(3):265–273.

193. Baldwin D, Woods R, Lawson R, et al. Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis. BMJ. 2011;342.

194. Ahmed S, Bachu R, Kotapati P, et al. Use of Gabapentin in the Treatment of Substance Use and Psychiatric Disorders: A Systematic Review. Front Psychiatry. 2019 May 7;10:228.

195. Kim HS, Kim EJ. Effects of Relaxation Therapy on Anxiety Disorders: A Systematic Review and Meta-analysis. Arch Psychiatr Nurs. 2018;32(2):278-284.

196. Wang J, Wu X, Lai W, et al. Prevalence of depression and depressive symptoms among outpatients: a systematic review and meta-analysis. BMJ Open. 2017 Aug 23;7(8):e017173.

197. Российское общество психиатров. Биполярное аффективное расстройство. 2021. 161 с.

198. Симуткин Г.Г., Бохан Н.А., Иванова С.А. Вероятностная диагностика биполярного аффективного расстройства: современные подходы, возможности и ограничения. Томск. 2023. 162 с.

199. Daveney J, Panagioti M, Waheed W, et al. Unrecognized bipolar disorder in patients with depression managed in primary care: A systematic review and meta-analysis. General Hospital Psychiatry. 2019;58:71-76.

200. Yildiz A, Siafis S, Mavridis D, et al. Comparative efficacy and tolerability of pharmacological interventions for acute bipolar depression in adults: a systematic review and network meta-analysis. The Lancet Psychiatry. 2023;9:693-705.

201. Cerimele JM, Chwastiak LA, Dodson S, et al. The Prevalence of Bipolar Disorder in Primary Care Patients With Depression or Other Psychiatric Complaints: A Systematic Review. Psychosomatics. 2013;54(6):515-24.

202. Amick HR, Gartlehner G, Gaynes BN, et al. Comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder: systematic review and meta-analysis. BMJ. 2015;351.

203. Gartlehner G, Dobrescu A, Chapman A, et al. Nonpharmacologic and Pharmacologic Treatments of Adult Patients With Major Depressive Disorder: A Systematic Review and Network Meta-analysis for a Clinical Guideline by the American College of Physicians. Ann Intern Med. 2023;2:196-211.

204. Cuijpers P, Oud M, Karyotaki E, et al. Psychologic Treatment of Depression Compared With Pharmacotherapy and Combined Treatment in Primary Care: A Network Meta-Analysis. Ann Fam Med. 2021;19(3):262-270.

205. Krijnen-de Bruin E, Scholten W, Muntingh A, et al. Psychological interventions to prevent relapse in anxiety and depression: A systematic review and meta-analysis. PLoS One. 2022 Aug 12;17(8):e0272200.

206. Kuyken W, Hayes R, Barrett B, et al. Effectiveness and cost-effectiveness of mindfulness-based cognitive therapy compared with maintenance antidepressant treatment in the prevention of depressive relapse or recurrence. The Lancet. 2015;386:63-73.

207. Bockting CLH, Klein NS, Elgersma HJ, et al. Effectiveness of preventive cognitive therapy while tapering antidepressants versus maintenance antidepressant treatment versus their combination in prevention of depressive relapse or recurrence (DRD study): a three-group, multicentre, randomised controlled trial. Lancet Psychiatry. 2018;5(5):401-410.

208. Breedvelt J, Warren F, Segal Z, et al. Continuation of Antidepressants vs Sequential Psychological Interventions to Prevent Relapse in Depression: An Individual Participant Data Meta-analysis. JAMA Psychiatry. 2021;8:868-875.

209. Cuijpers P, Noma H, Karyotaki E, et al. A network meta-analysis of the effects of psychotherapies, pharmacotherapies and their combination in the treatment of adult depression. World Psychiatry. 2020;19(1):92-107.

210. Furukawa TA, Shinohara K, Sahker E, et al. Initial treatment choices to achieve sustained response in major depression: a systematic review and network meta-analysis. World Psychiatry. 2021;20(3):387-396.

211. Guidi J, Fava G. Sequential Combination of Pharmacotherapy and Psychotherapy in Major Depressive Disorder: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2021;3:261-269.

212. Noetel M, Sanders T, Gallardo-Gómez D, et al. Effect of exercise for depression: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2024;384:e075847.

213. Schuch F, Vancampfort D, Firth J, et al. Physical activity and sedentary behavior in people with major depressive disorder: A systematic review and meta-analysis. Journal of Affective Disorders. 2017;210:139-150.

214. Schuch F, Vancampfort D, Richards J, et al. Exercise as a treatment for depression: A meta-analysis adjusting for publication bias. Journal of Psychiatric Research. 2016;77:42-51.

215. Kvam S, Kleppe C, Nordhus I, et al. Exercise as a treatment for depression: A meta-analysis. Journal of Affective Disorders. 2016;202:67-86.

216. Haddad M, Walters P, Phillips R, et al. Detecting depression in patients with coronary heart disease: a diagnostic evaluation of the PHQ-9 and HADS-D in primary care, findings from the UPBEAT-UK study. PLoS One. 2013 Oct 10;8(10):e78493.

217. Yuan J, Ding R, Wang L, et al. Screening for depression in acute coronary syndrome patients: A comparison of Patient Health Questionnaire-9 versus Hospital Anxiety and Depression Scale-Depression. Journal of Psychosomatic Research. 2019;121:24-28..

218. Frasure-Smith N, Lesperance F. Depression and Anxiety as Predictors of 2-Year Cardiac Events in Patients With Stable Coronary Artery Disease. Arch Gen Psychiatry 2008;65:62-71.

219. Krittanawong C, Maitra N, Qadeer Y, et al. Association of Depression and Cardiovascular Disease. The American Journal of Medicine. 2023;9:881-895.

220. Harshfield E, Pennells L, Schwartz J, et al. Association Between Depressive Symptoms and Incident Cardiovascular Diseases. JAMA. 2020;23:2396-2405.

221. Lee S, Yun J, Ko S, et al. Impacts of gender and lifestyle on the association between depressive symptoms and cardiovascular disease risk in the UK Biobank. Scientific Reports. 2023;1:10758.

222. Rajan S, McKee M, Rangarajan S, et al. Association of Symptoms of Depression With Cardiovascular Disease and Mortality in Low-, Middle-, and High-Income Countries. JAMA Psychiatry. 2020;10:1052-1063.

223. Chen X, Liu Z, Yang Y, et al. Depression Status, Lifestyle, and Metabolic Factors With Subsequent Risk for Major Cardiovascular Events: The China Cardiometabolic Disease and Cancer Cohort (4C) Study. Front Cardiovasc Med. 2022 May 26;9:865063.

224. Wei J, Hou R, Zhang X, et al. The association of late-life depression with all-cause and cardiovascular mortality among community-dwelling older adults: systematic review and meta-analysis. British Journal of Psychiatry. 2019;215:449-455.

225. VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder. 2022. 159 p.

226. Lewis G, Marston L, Duffy L, et al. Maintenance or Discontinuation of Antidepressants in Primary Care. N Engl J Med. 2021;14:1257-1267.

227. Kato M, Hori H, Inoue T, et al. Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis. Mol Psychiatry. 2021;26(1):118-133.

228. Zhou D, Lv Z, Shi L, et al. Effects of antidepressant medicines on preventing relapse of unipolar depression: a pooled analysis of parametric survival curves. Psychol Med. 2022;52(1):48-56.

229. Liu X, Momen NC, Molenaar N, et al. Discontinuation of antidepressants: Is there a minimum time on treatment that will reduce relapse risk? J Affect Disord. 2021 Jul 1;290:254-260.

230. Leung LB, Chu K, Rose D, et al. Electronic Population-Based Depression Detection and Management Through Universal Screening in the Veterans Health Administration. JAMA Netw Open. 2022;5(3):e221875.

231. Brinck-Claussen UØ, Curth NK, Christensen K, et al. Improving the precision of depression diagnosis in general practice: a cluster-randomized trial. BMC Fam Pract. 2021 May 7;22(1):88.

232. Löwe B, Scherer M, Braunschneider L, et al. Clinical effectiveness of patient-targeted feedback following depression screening in general practice (GET.FEEDBACK.GP): an investigator-initiated, prospective, multicentre, three-arm, observer-blinded, randomised controlled trial in Germany. The Lancet Psychiatry. 2024.

233. Moradi Y, Albatineh A, Mahmoodi H, et al. The relationship between depression and risk of metabolic syndrome: a meta-analysis of observational studies. Clinical Diabetes and Endocrinology. 2021;1:4.

234. Amare AT, Schubert KO, Klingler-Hoffmann M, et al. The genetic overlap between mood disorders and cardiometabolic diseases: a systematic review of genome wide and candidate gene studies. Transl Psychiatry. 2017 Jan 24;7(1):e1007.

235. Herring MP, Puetz TW, O'Connor PJ, et al. Effect of Exercise Training on Depressive Symptoms Among Patients With a Chronic Illness: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Arch Intern Med 2012;172(2):101-11.

236. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. The Lancet. 2018;391:1357–1366.

237. Li CT, Bai YM, Huang YL, et al. Association between antidepressant resistance in unipolar depression and subsequent bipolar disorder: cohort study. Br J Psychiatry 2012;200(1):45-51.

238. Российское общество психиатров. Посттравматическое стрессовое расстройство. 2023. 200 c.

239. Coventry PA, Meader N, Melton H, et al. Psychological and pharmacological interventions for posttraumatic stress disorder and comorbid mental health problems following complex traumatic events: Systematic review and component network meta-analysis. PLoS Med. 2020 Aug 19;17(8):e1003262.

240. Merz J, Schwarzer G, Gerger H. Comparative Efficacy and Acceptability of Pharmacological, Psychotherapeutic, and Combination Treatments in Adults With Posttraumatic Stress Disorder: A Network Meta-analysis. JAMA Psychiatry. 2019;76(9):904–913.

241. Lee DJ, Schnitzlein CW, Wolf JP, et al. Psychotherapy versus pharmacotherapy for posttraumatic stress disorder: systemic review and meta-analyses to determine first-line treatments. Depress Anxiety. 2016;33(9):792-806.

242. Lewis C, Roberts NP, Andrew M, et al. Psychological therapies for post-traumatic stress disorder in adults: systematic review and meta-analysis. Eur J Psychotraumatol. 2020 Mar 10;11(1):1729633.

243. Rauch SAM, Kim HM, Powell C, et al. Efficacy of Prolonged Exposure Therapy, Sertraline Hydrochloride, and Their Combination Among Combat Veterans With Posttraumatic Stress Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2019;76(2):117–126.

244. Phelps AJ, Lethbridge R, Brennan S, et al. Australian guidelines for the prevention and treatment of posttraumatic stress disorder: Updates in the third edition. Australian & New Zealand Journal of Psychiatry. 2022;56(3):230-247.

245. Zoellner L, Roy-Byrne P, Mavissakalian M, et al. Doubly Randomized Preference Trial of Prolonged Exposure Versus Sertraline for Treatment of PTSD. AJP. 2019;4:287-296.

246. Williams T, Phillips NJ, Stein DJ, Ipser JC. Pharmacotherapy for posttraumatic stress disorder (PTSD). Cochrane Database of Systematic Reviews 2022, Issue 3. Art. No.: CD002795.

247. de Moraes Costa G, Zanatta FB, Ziegelmann PK, et al. Pharmacological treatments for adults with post-traumatic stress disorder: A network meta-analysis of comparative efficacy and acceptability. J Psychiatr Res. 2020;130:412-420.

248. Cipriani A, Williams T, Nikolakopoulou A, et al. Comparative efficacy and acceptability of pharmacological treatments for post-traumatic stress disorder in adults: a network meta-analysis. Psychol Med. 2018;48(12):1975-1984.

249. LeardMann CA, Kelton ML, Smith B, et al. Prospectively assessed posttraumatic stress disorder and associated physical activity. Public Health Rep. 2011 May-Jun;126(3):371-83.

250. Jadhakhan F, Lambert N, Middlebrook N, et al. Is exercise/physical activity effective at reducing symptoms of post-traumatic stress disorder in adults — A systematic review. Frontiers in Psychology. 2022;13.

251. Björkman F, Ekblom Ö. Physical Exercise as Treatment for PTSD: A Systematic Review and Meta-Analysis. Mil Med. 2022 Aug 25;187(9-10):e1103-e1113.

252. Guina J, Rossetter SR, Derhodes BJ, et al. Benzodiazepines for PTSD: A Systematic Review and Meta-Analysis. J Psychiatr Pract. 2015;21(4):281-303.

253. Gates M, Holowka D, Vasterling J, et al. Posttraumatic Stress Disorder in Veterans and Military Personnel: Epidemiology, Screening, and Case Recognition. Psychological services. 2012;9:361-382.

254. ECNP/EBC. The size and burden of mental disorders and other disorders of the brain in Europe 2010. European Neuropsychopharmacology. 2011;21:655–679

255. Huo N, Vemuri P, Graff-Radford J, et al. Sex Differences in the Association Between Midlife Cardiovascular Conditions or Risk Factors With Midlife Cognitive Decline. Neurology. 2022 Feb 8;98(6):e623-e632.

256. Liang X, Huang Y, Han X. Associations between coronary heart disease and risk of cognitive impairment: A meta-analysis. Brain Behav. 2021;11(5):e02108.

257. Adelborg K, Horváth-Puhó E, Ording A, et al. Heart failure and risk of dementia: a Danish nationwide population-based cohort study. Eur J Heart Fail. 2017;19(2):253-260.

258. Li Chenglong, Zhu Yidan, Ma Yanjun, et al. Association of Cumulative Blood Pressure With Cognitive Decline, Dementia, and Mortality. Journal of the American College of Cardiology. 2022;14:1321-1335.

259. Kuźma E, Lourida I, Moore SF, et al. Stroke and dementia risk: A systematic review and meta-analysis. Alzheimers Dement. 2018;14(11):1416–1426.

260. Zuin M, Roncon L, Passaro A, et al. Risk of dementia in patients with atrial fibrillation: Short versus long follow-up. A systematic review and meta-analysis. International Journal of Geriatric Psychiatry. 2021;10:1488-1500.

261. Российское общество психиатров, Российская ассоциация геронтологов и гериатров. Когнитивные расстройства у лиц пожилого и старческого возраста. 2020. 239 с.

262. Patnode CD, Perdue LA, Rossom RC, et al. Screening for Cognitive Impairment in Older Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2020 Feb 25;323(8):764-785.

263. Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER). The Lancet. 2015;385:2255-2263.

264. Na R, Yang J, Yeom Y, et al. A Systematic Review and Meta-Analysis of Nonpharmacological Interventions for Moderate to Severe Dementia. Psychiatry Investig. 2019;16(5):325-335.

265. Woods B, Rai HK, Elliott E, et al. Cognitive stimulation to improve cognitive functioning in people with dementia. Cochrane Database of Systematic Reviews 2023, Issue 1. Art. No.: CD005562.

266. Kudlicka A, Martyr A, Bahar-Fuchs A, et al. Cognitive rehabilitation for people with mild to moderate dementia. Cochrane Database of Systematic Reviews 2023, Issue 6. Art. No.: CD013388.

267. Bahar-Fuchs A, Martyr A, Goh A, et al. Cognitive training for people with mild to moderate dementia. Cochrane Database of Systematic Reviews 2019, Issue 3. Art. No.: CD013069.

268. Kishi T, Matsunaga S, Oya K, et al. Memantine for Alzheimer's Disease: An Updated Systematic Review and Meta-analysis. J Alzheimers Dis. 2017;60(2):401-425.

269. McShane R, Westby MJ, Roberts E, et al. Memantine for dementia. Cochrane Database Syst Rev. 2019 Mar 20;3(3):CD003154.

270. Birks JS, Grimley Evans J. Rivastigmine for Alzheimer's disease. Cochrane Database of Systematic Reviews 2015, Issue 4. Art. No.: CD001191.

271. Vaci N, Koychev I, Kim C, et al. Real-world effectiveness, its predictors and onset of action of cholinesterase inhibitors and memantine in dementia: retrospective health record study. The British Journal of Psychiatry. 2021;218:261-267.

272. Matsunaga S, Kishi T, Iwata N, et al. Memantine monotherapy for Alzheimer's disease: a systematic review and meta-analysis. PLoS One. 2015;10(4):e0123289.

273. Saragih I, Tonapa S, Saragih I, et al. Effects of cognitive stimulation therapy for people with dementia: A systematic review and meta-analysis of randomized controlled studies. International Journal of Nursing Studies. 2022;128:104181.

274. Rojas-Fernandez CH. Little Evidence That Cholinesterase Inhibitors Prevent Progression of Mild Cognitive Impairment to Dementia, but They Are Associated With Adverse Effects. Evid Based Ment Health. 2013;16(2):39

275. Halling A, Berglund J. Association of diagnosis of ischaemic heart disease, diabetes mellitus and heart failure with cognitive function in the elderly population. Eur J Gen Pract. 2006;12(3):114-9.

276. Mulligan M, Murphy R, Reddin C, et al. Population attributable fraction of hypertension for dementia: global, regional, and national estimates for 186 countries. eClinicalMedicine. 2023;60.

277. McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. Cochrane Database of Systematic Reviews 2016, Issue 1.

278. Davis K, Bishara D, Perera G, et al. Benefits and Harms of Statins in People with Dementia: A Systematic Review and Meta-Analysis. J Am Geriatr Soc. 2020;68(3):650-658.

279. Parish S, Mafham M, Offer A, et al. Effects of aspirin on dementia and cognitive function in diabetic patients: the ASCEND trial. European Heart Journal. 2022 ;43(21):2010-9.

280. Doyle F, McGee H, Conroy R, et al. Systematic Review and Individual Patient Data Meta-Analysis of Sex Differences in Depression and Prognosis in Persons With Myocardial Infarction: A MINDMAPS Study. Psychosomatic Medicine 2015;77:419–28.

281. Meijer A, Conradi HJ, Bos EH, et al. Adjusted prognostic association of depression following myocardial infarction with mortality and cardiovascular events: individual patient data meta-analysis. Br J Psychiatry 2013;203(2):90-102.

282. Li J, Ji F, Song J, et al. Anxiety and clinical outcomes of patients with acute coronary syndrome: a meta-analysis. BMJ Open. 2020 Jul 9;10(7):e034135.

283. Roest AM, Martens EJ, Denollet J, et al. Prognostic Association of Anxiety Post Myocardial Infarction With Mortality and New Cardiac Events: A Meta-Analysis. Psychosom Med 2010;72(6):563-9.

284. Kronish IM, Edmondson D, Moise N, et al. Posttraumatic stress disorder in patients who rule out versus rule in for acute coronary syndrome. Gen Hosp Psychiatry. 2018 Jul-Aug;53:101-107.

285. Edmondson D, Richardson S, Falzon L, et al. Posttraumatic stress disorder prevalence and risk of recurrence in acute coronary syndrome patients: a meta-analytic review. PLoS One. 2012;7(6):e38915.

286. Gustad LT, Laugsand LE, Janszky I, et al. Symptoms of anxiety and depression and risk of acute myocardial infarction: the HUNT 2 study. Eur Heart J. 2014;35(21):1394-1403.

287. Rosengren A, Hawken S, Ounpuu S, et al. Association of psychosocial risk factors with risk of acute myocardial infarction in 11 119 cases and 13 648 controls from 52 countries (the INTERHEART study): case-control study. Lancet 2004;364(9438):953-62.

288. Jeffrey FS, Timothy C, Angelique Z, et al. Anxiety disorders increase risk for incident myocardial infarction in depressed and nondepressed Veterans Administration patients. American heart journal. 2010;159[5]:772-779.

289. Chen YH, Tsai SY, Lee HC, et al. Increased Risk of Acute Myocardial Infarction for Patients With Panic Disorder: A Nationwide Population-Based Study. Psychosom Med. 2009;71(7):798-804.

290. Flygare O, Boberg J, Rück C, et al. Association of anxiety or depression with risk of recurrent cardiovascular events and death after myocardial infarction: A nationwide registry study. International Journal of Cardiology. 2023;381:120-127.

291. Lichtman JH, Froelicher ES, Blumenthal JA, et al. Depression as a Risk Factor for Poor Prognosis Among Patients With Acute Coronary Syndrome: Systematic Review and Recommendations. Circulation. 2014;129:1350–1369.

292. Myers V, Gerber Y, Benyamini Y, et al. Post-myocardial infarction depression: Increased hospital admissions and reduced adoption of secondary prevention measures - A longitudinal study. Journal of Psychosomatic Research. 2012;2(1):5-10.

293. Kim JM, Stewart R, Bae KY, et al. Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study. Psychol Med. 2015;45(8):1641-52.

294. Taylor CB, Youngblood ME, Catellier D, et al. Effects of Antidepressant Medication on Morbidity and Mortality in Depressed Patients After Myocardial Infarction. Arch Gen Psychiatry. 2005;62:792-798.

295. Glassman AH, O'Connor CM, Califf RM, et al. Sertraline Treatment of Major Depression in Patients With Acute MI or Unstable Angina. JAMA. 2002;288:701-709.

296. van Melle JP, de Jonge P, Honig A, et al. Effects of antidepressant treatment following myocardial infarction. Br J Psychiatry 2007;190:460-6.

297. Kim J, Stewart R, Lee Y, et al. Effect of Escitalopram vs Placebo Treatment for Depression on Long-term Cardiac Outcomes in Patients With Acute Coronary Syndrome. A Randomized Clinical Trial. JAMA. 2018;320(4):350–358.

298. Abdullah A, Eigbire G, Salama A, et al. Impact of delirium on patients hospitalized for myocardial infarction: A propensity score analysis of the National Inpatient Sample. Clin Cardiol. 2018;41(7):910-915.

299. Jäckel M, Zotzmann V, Wengenmayer T, et al. Incidence and predictors of delirium on the intensive care unit after acute myocardial infarction, insight from a retrospective registry. Catheterization and Cardiovascular Interventions. 2021;6:1072-1081.

300. Patil S, Gonuguntala K, Rojulpote C, et al. Delirium is an important predictor of mortality in elderly patients with ST-elevation myocardial infarction: insight from National Inpatient Sample database. Coron Artery Dis. 2020;31(8):665-670.

301. Kang H-J, Stewart R, Bae K-Y, et al. Effects of depression screening on psychiatric outcomes in patients with acute coronary syndrome: Findings from the K-DEPACS and EsDEPACS studies. Int J Card. 2015;190:114-121.

302. Kronish IM, Moise N, Cheung YK, et al. Effect of Depression Screening After Acute Coronary Syndromes on Quality of Life: The CODIACS-QoL Randomized Clinical Trial. JAMA Intern Med. 2020;180(1):45–53.

303. Sweda R, Siontis GCM, Nikolakopoulou A, et al. Antidepressant treatment in patients following acute coronary syndromes: a systematic review and Bayesian meta-analysis. ESC Heart Fail. 2020 Sep 16;7(6):3610–20.

304. Huang K-L, Fang C-J, Hsu C-C, et al. Myocardial infarction risk and antipsychotics use revisited: a meta-analysis of 10 observational studies. Journal of Psychopharmacology. 2017;31(12):1544-1555.

305. Yu ZH, Jiang HY, Shao L, et al. Use of antipsychotics and risk of myocardial infarction: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016;82(3):624-32.

306. Ben-Shoshan J, Segman-Rosenstveig Y, Arbel Y, et al. Comparison of Triggering and Nontriggering Factors in ST-Segment Elevation Myocardial Infarction and Extent of Coronary Arterial Narrowing. Am J Card. 2016;117(8):1219-1223.

307. Tofler GH, Kopel E, Klempfner R, et al. Triggers and Timing of Acute Coronary Syndromes. Am J Card. 2017;119(10):1560-1565.

308. Chan B, Buckley T, Tofler G, et al. Emotional Stress and Physical Exertion as Triggers of Acute Myocardial Infarction. American Journal of Cardiology. 2023;203:285-287.

309. Smyth A, O’Donnell M, Lamelas P, et al. Physical Activity and Anger or Emotional Upset as Triggers of Acute Myocardial Infarction. Circulation. 2016;134:1059-1067

310. Lissåker CT, Norlund F, Wallert J, et al. Persistent emotional distress after a first-time myocardial infarction and its association to late cardiovascular and non-cardiovascular mortality. Eur J Prev Cardiol. 2019;26(14):1510-1518.

311. Park Y, Bateman BT, Kim DH, et al. Use of haloperidol versus atypical antipsychotics and risk of in-hospital death in patients with acute myocardial infarction: cohort study. BMJ. 2018;360.

312. Kemp AH, Brunoni AR, Nunes MA, et al. The association between mood and anxiety disorders, and coronary heart disease in Brazil: a cross-sectional analysis on the Brazilian longitudinal study of adult health (ELSA-Brasil). Front Psychol. 2015;6:187.

313. Gan Y, Gong Y, Tong X, et al. Depression and the risk of coronary heart disease: a meta-analysis of prospective cohort studies. BMC Psychiatry. 2014;14(1):1-11.

314. Poole L, Steptoe A. Depressive symptoms predict incident chronic disease burden 10-years later: Findings from the English Longitudinal Study of Ageing (ELSA). Journal of Psychosomatic Research. 2018;113:30-36.

315. Herbst S, Pietrzak RH, Wagner J et al. Lifetime Major Depression is Associated With Coronary Heart Disease in Older Adults: Results From the National Epidemiologic Survey on Alcohol and Related Conditions. Psychosom Med 2007;69:729-34.

316. Roest AM, Martens EJ, de Jonge P, et al. Anxiety and Risk of Incident Coronary Heart Disease: A Meta-Analysis. J Am Coll Cardiol 2010;56(1):38-46.

317. Emdin CA, Odutayo A, Wong CX, et al. Meta-Analysis of Anxiety as a Risk Factor for Cardiovascular Disease. Am J Card. 2016;118(4):511-519.

318. Tully PJ, Turnbull DA, Beltrame J, et al. Panic disorder and incident coronary heart disease: a systematic review and meta-regression in 1131612 persons and 58111 cardiac events. Psychol Med. 2015;45(14):2909-20.

319. Akosile W, Colquhoun D, Young R, et al. The association between post-traumatic stress disorder and coronary artery disease: a meta-analysis. Australas Psychiatry. 2018;26(5):524-530.

320. Edmondson D, Kronish IM, Shaffer JA, et al. Posttraumatic stress disorder and risk for coronary heart disease: A meta-analytic review. American heart journal. 2013;166[5]:806-814.

321. Белялов Ф.И. Депрессия, тревога и стресс у пациентов с ишемической болезнью сердца. Терапевтический архив. 2017;89(8):104–109.

322. Derisi MM, Nasiri MJ, Aryan A, et al. Prevalence of psychiatric disorders in patients with ischemic heart disease: A systematic review and meta-analysis. J Res Med Sci. 2022 Feb 18;27:12.

323. Boyle SH, Samad Z, Becker RC, et al. Depressive Symptoms and Mental Stress-Induced Myocardial Ischemia in Patients With Coronary Heart Disease. Psychosom Med 2013;75(9):822-31.

324. Geovanini GR, Gowdak LHW, Pereira AC et al. OSA and depression are common and independently associated with refractory angina in patients with coronary artery disease. CHEST. 2014;146:73-80.

325. Schopfer DW, Regan M, Heidenreich PA, Whooley MA. Depressive Symptoms, Cardiac Disease Severity, and Functional Status in Patients With Coronary Artery Disease (from the Heart and Soul Study). Am J Card. 2016;118(9):1287-1292.

326. Papasavvas T, Alhashemi M, Micklewright D. Association Between Depressive Symptoms and Exercise Capacity in Patients With Heart Disease: A Meta-analysis. J Cardiopulm Rehabil Prev. 2017;37(4):239–49.

327. Lin S, Zhang H, Ma A. The association between depression and coronary artery calcification: A meta-analysis of observational studies. J Affect Disord. 2018;232:276-282.

328. Tusa N, Kautiainen H, Elfving P, et al. Depressive symptoms decrease health-related quality of life of patients with coronary artery disease and diabetes: a 12-month follow up study in primary care. Scand J Prim Health Care. 2023;41(3):276-286.

329. Martens EJ, de Jonge P, Na B, et al. Scared to Death? Generalized Anxiety Disorder and Cardiovascular Events in Patients With Stable Coronary Heart Disease: The Heart and Soul Study. Arch Gen Psychiatry 2010;67(7):750-8.

330. Tully PJ, Turnbull DA, Beltrame J, et al. Panic disorder and incident coronary heart disease: a systematic review and meta-regression in 1131612 persons and 58111 cardiac events. Psychol Med. 2015;45(14):2909-20.

331. Celano CM, Millstein RA, Bedoya CA, et al. Association between anxiety and mortality in patients with coronary artery disease: A meta-analysis. Am Heart J. 2015;170(6):1105-1115.

332. Vaccarino V, Sullivan S, Hammadah M, et al. Mental Stress–Induced-Myocardial Ischemia in Young Patients With Recent Myocardial Infarction. Circulation. 2018;137(8):794.

333. Wei J, Rooks C, Ramadan R, et al. Meta-analysis of mental stress-induced myocardial ischemia and subsequent cardiac events in patients with coronary artery disease. The American journal of cardiology 2014;114:187-192.

334. Liang X, Huang Y, Han X. Associations between coronary heart disease and risk of cognitive impairment: A meta-analysis. Brain Behav. 2021;11(5):e02108.

335. Laporte S, Chapelle C, Caillet P, et al. Bleeding risk under selective serotonin reuptake inhibitor (SSRI) antidepressants: A meta-analysis of observational studies. Pharmacol Res. 2017;118:19-32.

336. Magán I, Jurado-Barba R, Casado L, et al. Efficacy of psychological interventions on clinical outcomes of coronary artery disease: Systematic review and meta-analysis. Journal of Psychosomatic Research. 2022;153:110710.

337. Doyle F, Freedland K, Carney R, et al. Hybrid Systematic Review and Network Meta-Analysis of Randomized Controlled Trials of Interventions for Depressive Symptoms in Patients With Coronary Artery Disease. Psychosomatic Medicine. 2021;83.

338. Dibben G, Faulkner J, Oldridge N, et al. Exercise-based cardiac rehabilitation for coronary heart disease: a meta-analysis. European Heart Journal. 2023;6:452-469.

339. Gordon BR, McDowell CP, Hallgren M, et al. Association of Efficacy of Resistance Exercise Training With Depressive Symptoms. Meta-analysis and Meta-regression Analysis of Randomized Clinical Trials. JAMA Psychiatry. 2018;75(6):566–576.

340. Hallgren M, Kraepelien M, Öjehagen A, et al. Physical exercise and internet-based cognitive–behavioural therapy in the treatment of depression: randomised controlled trial. The British Journal of Psychiatry 2015;207:227-234.

341. Blumenthal JA, Sherwood A, Babyak MA, et al. Exercise and Pharmacological Treatment of Depressive Symptoms in Patients With Coronary Heart Disease: Results From the UPBEAT (Understanding the Prognostic Benefits of Exercise and Antidepressant Therapy) Study. J Am Coll Cardiol. 2012;60(12):1053-1063.

342. Bauer LK, Caro MA, Beach SR, et al. Effects of Depression and Anxiety Improvement on Adherence to Medication and Health Behaviors in Recently Hospitalized Cardiac Patients. The American journal of cardiology. 2012;109[10]:1266-1271.

343. Kronish IM, Woodward M, Sergie Z, et al. Meta-Analysis: Impact of Drug Class on Adherence to Antihypertensives. Circulation 2011;123(15):1611-21.

344. Lapa ME, Swabe GM, Rollman BL, et al. Assessment of Depression and Adherence to Guideline-Directed Medical Therapies Following Percutaneous Coronary Intervention. JAMA Netw Open. 2022;5(12):e2246317.

345. Kronish IM, Rieckmann N, Halm EA et al. Persistent depression affects adherence to secondary prevention behaviors after acute coronary syndromes. J Gen Intern Med. 2006;21(11):1178-83.

346. Dempe C, Jünger J, Hoppe S, et al. Association of anxious and depressive symptoms with medication nonadherence in patients with stable coronary artery disease. Journal of Psychosomatic Research. 2013;74(2):122-127.

347. Greaves D, Psaltis P, Ross T, et al. Cognitive outcomes following coronary artery bypass grafting: A systematic review and meta-analysis of 91,829 patients. International Journal of Cardiology. 2019;289:43-49.

348. van Dijk MR, Utens EM, Dulfer K, et al. Depression and anxiety symptoms as predictors of mortality in PCI patients at 10 years of follow-up. Eur J Prev Cardiol. 2016;23(5):552-8.

349. Zhang WY, Nan N, Song XT, et al. Impact of depression on clinical outcomes following percutaneous coronary intervention: a systematic review and meta-analysis. BMJ Open. 2019 Aug 20;9(8):e026445.

350. Geulayov G, Novikov I, Dankner D, Dankner R. Symptoms of depression and anxiety and 11-year all-cause mortality in men and women undergoing coronary artery bypass graft (CABG) surgery. J Psychosom Res. 2018;105:106-114.

351. Stenman M, Holzmann MJ, Sartipy U. Association between preoperative depression and long-term survival following coronary artery bypass surgery - A systematic review and meta-analysis. Int J Cardiol. 2016;222:462-466.

352. Bouchard V, Robitaille A, Perreault S, et al. Psychological distress, social support, and use of outpatient care among adult men and women with coronary artery disease or other non-cardiovascular chronic disease. Journal of Psychosomatic Research. 2023;165:111131.

353. Rawashdeh SI, Ibdah R, Kheirallah KA, et al. Prevalence Estimates, Severity, and Risk Factors of Depressive Symptoms among Coronary Artery Disease Patients after Ten Days of Percutaneous Coronary Intervention. Clin Pract Epidemiol Ment Health. 2021 Sep 16;17:103-113.

354. Pedersen SS, Denollet J, van Gestel YR, et al. Clustering of psychosocial risk factors enhances the risk of depressive symptoms 12-months post percutaneous coronary intervention. Eur J Cardiovasc Prev Rehabil. 2008;15(2):203-9.

355. Williams B, Riangwiwat T, Voyce S, et al. Burden and Predictors of Chest Pain-Related Health-Care Utilization Following Percutaneous Coronary Intervention. American Journal of Cardiology. 2021;160:31-39.

356. de Jager T, Dulfer K, Radhoe S, et al. Predictive value of depression and anxiety for long-term mortality: differences in outcome between acute coronary syndrome and stable angina pectoris. Int J Card. 2018;250:43-48.

357. Zhang H, Shao B, Wang Q, et al. Alcohol Consumption and Risk of Atrial Fibrillation: A Dose-Response Meta-Analysis of Prospective Studies. Frontiers in Cardiovascular Medicine. 2022;9.

358. Yang L, Chen H, Shu T, et al. Risk of incident atrial fibrillation with low-to-moderate alcohol consumption is associated with gender, region, alcohol category: a systematic review and meta-analysis. EP Europace. 2022;5:729-746.

359. Larsson SC, Drca N, Wolk A. Alcohol Consumption and Risk of Atrial Fibrillation: A Prospective Study and Dose-Response Meta-Analysis. J Am Coll Cardiol. 2014;64(3):281-289.

360. Gehi AK, Sears S, Goli N, et al. Psychopathology and symptoms of atrial fibrillation: implications for therapy. J Cardiovasc Electrophysiol. 2012;23(5):473-8.

361. Thompson TS, Barksdale DJ, Sears SF, et al. The effect of anxiety and depression on symptoms attributed to atrial fibrillation. Pacing Clin Electrophysiol. 2014;37(4):439-46.

362. Akintade BF, Chapa D, Friedmann E, Thomas SA. The influence of depression and anxiety symptoms on health-related quality of life in patients with atrial fibrillation and atrial flutter. J Cardiovasc Nurs. 2015;30(1):66-73.

363. Bamgbade BA, Sanghai SR, McManus DD, et al. Psychosocial and cognitive multimorbidity and health-related quality of life and symptom burden in older adults with atrial fibrillation: The systematic assessment of geriatric elements in atrial fibrillation (SAGE-AF) cohort study. Arch Gerontol Geriatr. 2020 Sep-Oct;90:104117.

364. Taylor EC, O'Neill M, Hughes LD, Moss-Morris R. Atrial fibrillation, quality of life and distress: a cluster analysis of cognitive and behavioural responses. Qual Life Res. 2022;31(5):1415-1425.

365. von Eisenhart Rothe A, Hutt F, Baumert J et al. Depressed mood amplifies heart-related symptoms in persistent and paroxysmal atrial fibrillation patients: a longitudinal analysis. Europace 2015;17:1354-1362.

366. Yu S, Zhao Q, Wu P, et al. Effect of anxiety and depression on the recurrence of paroxysmal atrial fibrillation after circumferential pulmonary vein ablation. J Cardiovasc Electrophysiol. 2012;23 Suppl 1:S17-23.

367. Efremidis M, Letsas KP, Lioni L, et al. Association of quality of life, anxiety, and depression with left atrial ablation outcomes. Pacing Clin Electrophysiol. 2014;37(6):703-11.

368. Giannone M, Filippini T, Whelton P, et al. Atrial Fibrillation and the Risk of Early-Onset Dementia: A Systematic Review and Meta-Analysis. Journal of the American Heart Association. 2022;14:e025653.

369. Zuin M, Roncon L, Passaro A, et al. Risk of dementia in patients with atrial fibrillation: Short versus long follow-up. A systematic review and meta-analysis. International Journal of Geriatric Psychiatry. 2021;10:1488-1500.

370. Koh Y, Lew L, Franke K, et al. Predictive role of atrial fibrillation in cognitive decline: a systematic review and meta-analysis of 2.8 million individuals . EP Europace. 2022;8:1229-1239.

371. Rosman L, Lampert R, Ramsey C, et al. Posttraumatic Stress Disorder and Risk for Early Incident Atrial Fibrillation: A Prospective Cohort Study of 1.1 Million Young Adults. Journal of the American Heart Association. 2019;19:e013741.

372. Voskoboinik A, Kalman J, De Silva A, et al. Alcohol Abstinence in Drinkers with Atrial Fibrillation. N Engl J Med. 2020;1:20-28.

373. Lee S, Choi E, Jung J, et al. Lower risk of stroke after alcohol abstinence in patients with incident atrial fibrillation: a nationwide population-based cohort study. European Heart Journal. 2021;46:4759-4768.

374. Lee J, Roh S, Yoon W, et al. Changes in alcohol consumption habits and risk of atrial fibrillation: a nationwide population-based study. European Journal of Preventive Cardiology. 2024;1:49-58.

375. Damanti S, Pasina L, Cortesi L, et al. Atrial Fibrillation: Possible Influences of Rate and Rhythm Control Strategy on Cognitive Performance. J Am Geriatr Soc. 2018;66(11):2178-2182.

376. Teppo K, Jaakkola J, Airaksinen K, et al. Mental Health Conditions and Nonpersistence of Direct Oral Anticoagulant Use in Patients With Incident Atrial Fibrillation: A Nationwide Cohort Study. Journal of the American Heart Association. 2022;6:e024119.

377. Lapa ME, Swabe GM, Magnani JW. Association of Depression and Adherence to Oral Anticoagulation in Patients With Atrial Fibrillation. J Am Heart Assoc. 2023 Nov 20:e031281.

378. Colquhoun D, Malawaraarachchi N, Ferreira-Jardim A, et al. Poor adherence to anticoagulant therapy: a call to screen and treat depression in patients with atrial fibrillation. Heart, Lung and Circulation. 2015;24:S389-S390.

379. Lampert R, Burg M, Jamner L, et al. Effect of b-blockers on triggering of symptomatic atrial fibrillation by anger or stress. Heart Rhythm. 2019;8:1167-1173.

380. Kim D, Yang P, Sung J, et al. Less dementia after catheter ablation for atrial fibrillation: a nationwide cohort study. European Heart Journal. 2020;47:4483-4493.

381. Mark DB, Anstrom KJ, Sheng S, et al. Effect of Catheter Ablation vs Medical Therapy on Quality of Life Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial. JAMA. 2019;321(13):1275-1285.

382. Al-Kaisey Ahmed M, Parameswaran Ramanathan, Bryant Christina, et al. Impact of Catheter Ablation on Cognitive Function in Atrial Fibrillation. JACC: Clinical Electrophysiology. 2023;7Part2:1024-1034.

383. Harrison S, Buckley B, Austin P, et al. Catheter ablation and lower risk of incident dementia and mortality in older adults with atrial fibrillation. Journal of the American Geriatrics Society. 2023;11:3357-3366.

384. Thrall G, Lip GYH, Carroll D, et al. Depression, Anxiety, and Quality of Life in Patients With Atrial Fibrillation. Chest 2007;132:1259-64.

385. Wu H, Li C, Li B, et al. Psychological factors and risk of atrial fibrillation: A meta-analysis and systematic review. International Journal of Cardiology. 2022;362:85-92.

386. Shi S, Liu T, Liang J, Hu D, Yang B. Depression and Risk of Sudden Cardiac Death and Arrhythmias: A Meta-Analysis. Psychosomatic Medicine. 2017;79(2).

387. Kim Y, Lee K, Han K, et al. Association of Depression With Atrial Fibrillation in South Korean Adults. JAMA Network Open. 2022;1:e2141772-e2141772.

388. Cheng YF, Leu HB, Su CC, et al. Association Between Panic Disorder and Risk of Atrial Fibrillation: A Nationwide Study. Psychosom Med 2013;75(1):30-5.

389. Graff S, Fenger-Grøn M, Christensen B, et al. Long-term risk of atrial fibrillation after the death of a partner. Open Heart. 2016;3(1).

390. Wei D, Olofsson T, Chen H, et al. Death of a child and the risk of atrial fibrillation: a nationwide cohort study in Sweden. European Heart Journal. 2021;15:1489-1495.

391. Suzuki H, Ohira T, Takeishi Y, et al. Increased prevalence of atrial fibrillation after the Great East Japan Earthquake: Results from the Fukushima Health Management Survey. Int J Card. 2015;198:102-105.

392. Kupper N, van den Broek KC, Widdershoven J, Denollet J. Subjectively reported symptoms in patients with persistent atrial fibrillation and emotional distress. Front Psychol. 2013;4:192.

393. Perret-Guillaume C, Briancon S, Wahl D, et al. Quality of Life in elderly inpatients with atrial fibrillation as compared with controlled subjects. J Nutr Health Aging. 2010;14(2):161-6.

394. Sadlonova M, Salzmann S, Senges J, et al. Generalized anxiety is a predictor of impaired quality of life in patients with atrial fibrillation: Findings from the prospective observational ARENA study. Journal of Psychosomatic Research. 2024;176:111542.

395. Gardarsdottir M, Sigurdsson S, Aspelund T, et al. Atrial fibrillation is associated with decreased total cerebral blood flow and brain perfusion. EP Europace. 2018;8:1252-1258.

396. Singh-Manoux A, Fayosse A, Sabia S, et al. Atrial fibrillation as a risk factor for cognitive decline and dementia. Eur Heart J. 2017;38(34):2612-2618.

397. Koh Y, Lew L, Franke K, et al. Predictive role of atrial fibrillation in cognitive decline: a systematic review and meta-analysis of 2.8 million individuals . EP Europace. 2022;8:1229-1239.

398. Marcus G, Vittinghoff E, Whitman I, et al. Acute Consumption of Alcohol and Discrete Atrial Fibrillation Events. Ann Intern Med. 2021;11:1503-1509.

399. Gallagher C, Hendriks JML, Elliott AD, et al. Alcohol and incident atrial fibrillation – A systematic review and meta-analysis. Int J Card. 2017;246:46-52.

400. Stecker EC, Reinier K, Marijon E, et al. Public health burden of sudden cardiac death in the United States. Circ Arrhythm Electrophysiol. 2014;7(2):212-7.

401. Salvo F, Pariente A, Shakir S, et al. Sudden cardiac and sudden unexpected death related to antipsychotics: A meta-analysis of observational studies.Clin Pharmacol Ther. 2016;99(3):306-14.

402. Ray WA, Chung CP, Murray KT, et al. Atypical Antipsychotic Drugs and the Risk of Sudden Cardiac Death. The New England Journal of Medicine 2009;360(3):225-35.

403. Murray-Thomas T, Jones ME, Patel D, et al. Risk of mortality (including sudden cardiac death) and major cardiovascular events in atypical and typical antipsychotic users: a study with the general practice research database. Cardiovasc Psychiatry Neurol. 2013;2013:247486.

404. Wang M, Szepietowska B, Polonsky B, et al. Risk of Cardiac Events Associated With Antidepressant Therapy in Patients With Long QT Syndrome. Am J Card. 2018;121(2):182-187.

405. Beach SR, Kostis WJ, Celano CM, et al. Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation. J Clin Psychiatry. 2014;75(5):e441-9.

406. Schwartz PJ, Priori SG, Spazzolini C, et al. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation. 2001 Jan 2;103(1):89-95.

407. Hintsa T, Määttänen I, Hintsanen M, et al. Work stress and the long QT syndrome: high job strain and effort-reward imbalance at work associated with arrhythmic risk in the long QT syndrome. J Occup Environ Med. 2013;55(12):1387-93.

408. Shimizu W, Noda T, Takaki H, et al. Diagnostic value of epinephrine test for genotyping LQT1, LQT2, and LQT3 forms of congenital long QT syndrome. Heart Rhythm. 2004;1(3):276-83.

409. Ghezzi E, Sharman R, Selvanayagam J, et al. Burden of mood symptoms and disorders in implantable cardioverter defibrillator patients: a systematic review and meta-analysis of 39 954 patients. EP Europace. 2023;25(6):euad130.

410. Miller J, Thylén I, Elayi S, et al. Multi-morbidity burden, psychological distress, and quality of life in implantable cardioverter defibrillator recipients: Results from a nationwide study. Journal of Psychosomatic Research. 2019;120:39-45.

411. Januszkiewicz Ł, Barra S, Providencia R, et al. Long-term quality of life and acceptance of implantable cardioverter-defibrillator therapy: results of the European Heart Rhythm Association survey. EP Europace. 2022;5:860-867.

412. Fanoe S, Kristensen D, Fink-Jensen A, et al. Risk of arrhythmia induced by psychotropic medications: a proposal for clinical management. European Heart Journal 2014;35:1306-1315.

413. Белялов Ф.И. Белялов Ф.И. Аритмии сердца. 9-e изд. Москва: ГЭОТАР-Медиа, 2023. с. 412–415 с.

414. Jeon SH, Jaekal J, Lee SH, et al. Effects of nortriptyline on QT prolongation: a safety pharmacology study. Hum Exp Toxicol. 2011;30(10):1649-56.

415. Funk KA, Bostwick JR. A comparison of the risk of QT prolongation among SSRIs. Ann Pharmacother. 2013;47(10):1330-41.

416. Polcwiartek C, Kragholm K, Schjerning O, et al. Cardiovascular safety of antipsychotics: a clinical overview. Expert Opin Drug Saf. 2016;15(5):679-88.

417. Ray WA, Chung CP, Murray KT, et al. Atypical Antipsychotic Drugs and the Risk of Sudden Cardiac Death. The New England Journal of Medicine 2009;360(3):225-35.

418. NHS Foundation. Guidance on the Use of Antipsychotics. 2018. 60 p.

419. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Third edition. 2021. 299 p.

420. Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multiepisode schizophrenia: a systematic review and network meta-analysis. The Lancet. 2019;10202:939-951.

421. Fayssoil A, Issi J, Guerbaa M, et al. Torsade de pointes induced by citalopram and amiodarone. Ann Cardiol Angeiol (Paris). 2011;60(3):165-8.

422. Bundgaard J, Thune J, Nielsen J, et al. The impact of implantable cardioverter-defibrillator implantation on health-related quality of life in the DANISH trial. EP Europace. 2019;6:900-908.

423. Pan Y., Cai W., Cheng Q., Dong W., An T., Wang J. Association between anxiety and hypertension: a systematic review and meta-analysis of epidemiological studies. Neuropsychiatr Dis Treat. 2015;11:1121-1130 https://doi.org/10.2147/NDT.S77710

424. Wu E-L, Chien IC, Lin C-H. Increased risk of hypertension in patients with anxiety disorders: A population-based study. Journal of Psychosomatic Research. 2014;77(6):522-527.

425. Meng L, Chen D, Yang Y, et al. Depression increases the risk of hypertension incidence: a meta-analysis of prospective cohort studies. J Hypertens. 2012;30(5):842-51.

426. Wu E-L, Chien IC, Lin C-H, Chou Y-J, Chou P. Increased risk of hypertension in patients with major depressive disorder: A population-based study. Journal of Psychosomatic Research. 2012;73(3):169-174.

427. Lim L, Solmi M, Cortese S, et al. Association between anxiety and hypertension in adults: A systematic review and meta-analysis. Neuroscience & Biobehavioral Reviews. 2021;131:96-119.

428. Abouzeid M, Kelsall HL, Forbes AB, et al. Posttraumatic stress disorder and hypertension in Australian veterans of the 1991 Gulf War. Journal of Psychosomatic Research. 2012;72(1):33-38.

429. Sumner JA, Kubzansky LD, Roberts AL, et al. Post-traumatic stress disorder symptoms and risk of hypertension over 22 years in a large cohort of younger and middle-aged women. Psychol Med. 2016;46(15):3105-3116.

430. Abell J, Kivimäki M, Dugravot A, et al. Association between systolic blood pressure and dementia in the Whitehall II cohort study: role of age, duration, and threshold used to define hypertension. European Heart Journal. 2018;33:3119-3125.

431. Emdin C, Rothwell P, Salimi-Khorshidi G, et al. Blood Pressure and Risk of Vascular Dementia. Stroke. 2016;6:1429-1435.

432. Li Chenglong, Zhu Yidan, Ma Yanjun, et al. Association of Cumulative Blood Pressure With Cognitive Decline, Dementia, and Mortality. Journal of the American College of Cardiology. 2022;14:1321-1335.

433. Cunningham EL, Todd SA, Passmore P, et al. Pharmacological treatment of hypertension in people without prior cerebrovascular disease for the prevention of cognitive impairment and dementia. Cochrane Database of Systematic Reviews 2021, Issue 5. Art. No.: CD004034.

434. Hughes D, Judge C, Murphy R, et al. Association of Blood Pressure Lowering With Incident Dementia or Cognitive Impairment: A Systematic Review and Meta-analysis. JAMA. 2020;323(19):1934–1944.

435. Forette F, Seux ML, Staessen JA, et al. The Prevention of Dementia With Antihypertensive Treatment. Arch Intern Med. 2002;162:2046-52.

436. Peters R, Xu Y, Fitzgerald O, et al. Blood pressure lowering and prevention of dementia: an individual patient data meta-analysis. Eur Heart J. 2022 Dec 21;43(48):4980-4990.

437. Wang L, Liu Q, Sun D, et al. Effects of Combination Treatment in Hypertensive Patients with Depression: A Systematic Review and Meta-Analysis of 27 Randomized Controlled Trials. Ther Clin Risk Manag. 2022 Mar 5;18:197-211.

438. Graham N, Ward J, Mackay D, et al. Impact of major depression on cardiovascular outcomes for individuals with hypertension: prospective survival analysis in UK Biobank. BMJ Open. 2019 Sep 30;9(9):e024433.

439. Ogedegbe G, Pickering TG, Clemow L, et al. The Misdiagnosis of Hypertension: The Role of Patient Anxiety. Arch Intern Med 2008;168(22):2459-65.

440. Spruill TM, Pickering TG, Schwartz JE, et al. The impact of perceived hypertension status on anxiety and the white coat effect. Ann Behav Med. 2007;34(1):1-9.

441. Jhalani J, Goyal T, Clemow L, et al. Anxiety and outcome expectations predict the white-coat effect. Blood Press Monit. 2005;10(6):317-9.

442. Li Z., Li Y., Chen L., Chen P., Hu Y. Prevalence of Depression in Patients With Hypertension: A Systematic Review and Meta-Analysis. Medicine (Baltimore). 2015 Aug;94(31):e1317. doi: 10.1097/MD.0000000000001317.

443. Williamson JD, Pajewski NM, Auchus AP, et al. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA. 2019;321(6):553–561.

444. Stuhec M, Keuschler J, Serra-Mestres J, Isetta M. Effects of different antihypertensive medication groups on cognitive function in older patients: A systematic review. European Psychiatry. 2017;46:1-15.

445. den Brok M, van Dalen J, Abdulrahman H, et al. Antihypertensive Medication Classes and the Risk of Dementia: A Systematic Review and Network Meta-Analysis. J Am Med Dir Assoc. 2021;22(7):1386-1395.e15.

446. Chen YJ, Li LJ, Tang WL, et al. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. Cochrane Database Syst Rev. 2018 Nov 14;11(11):CD008170.

447. Breeden M, Gillis A, Salas J, et al. Antidepressant treatment and blood pressure control in patients with comorbid depression and treatment resistant hypertension. Journal of Psychosomatic Research. 2022;153:110692.

448. Breeden M, Gillis A, Salas J, et al. Antidepressant treatment and blood pressure control in patients with comorbid depression and treatment resistant hypertension. Journal of Psychosomatic Research. 2022;153:110692.

449. Turvey CL, Schultz K, Arndt S, et al. Prevalence and correlates of depressive symptoms in a community sample of people suffering from heart failure. J Am Geriatr Soc 2002;50(12):2003-8.

450. Chobufo M, Khan S, Agbor V, et al. 10-Year trend in the prevalence and predictors of depression among patients with heart failure in the USA from 2007-2016. International Journal of Cardiology. 2020;301:123-126.

451. Angermann CE, Gelbrich G, Stork S, et al. Somatic correlates of comorbid major depression in patients with systolic heart failure. Int J Cardiol. 2011;147(1):66-73.

452. Khodneva Y, Goyal P, Levitan E, et al. Depressive Symptoms and Incident Hospitalization for Heart Failure: Findings From the REGARDS Study. Journal of the American Heart Association. 2022;7:e022818.

453. Gustad LT, Laugsand LE, Janszky I, Dalen H, Bjerkeset O. Symptoms of anxiety and depression and risk of heart failure: the HUNT Study. Eur J Heart Fail 2014;16:861–870.

454. Garfield LD, Scherrer JF, Hauptman PJ, et al. Association of Anxiety Disorders and Depression With Incident Heart Failure. Psychosomatic Medicine. 2014;76(2):128-36.

455. Lossnitzer N, Herzog W, Stork S, et al. Incidence rates and predictors of major and minor depression in patients with heart failure. Int J Cardiol. 2013;167(2):502-7.

456. Kewcharoen J, Tachorueangwiwat C, Kanitsoraphan C, et al. Association between depression and increased risk of readmission in patients with heart failure: a systematic review and meta-analysis. Minerva Cardiol Angiol. 2021;69(4):389-397.

457. Machado MO, Veronese N, Sanches M, et al. The association of depression and all-cause and cause-specific mortality: an umbrella review of systematic reviews and meta-analyses. BMC Med 2018;16:112

458. Patel N, Chakraborty S, Bandyopadhyay D, et al. Association between depression and readmission of heart failure: A national representative database study. Prog Cardiovasc Dis. 2020 Sep-Oct;63(5):585-590. doi: 10.1016/j.pcad.2020.03.014.

459. Gathright EC, Goldstein CM, Josephson RA, Hughes JW. Depression increases the risk of mortality in patients with heart failure: A meta-analysis. J Psychosom Res. 2017;94:82-89.

460. IsHak WW, Hamilton MA, Korouri S, et al. Comparative Effectiveness of Psychotherapy vs Antidepressants for Depression in Heart Failure: A Randomized Clinical Trial. JAMA Netw Open. 2024;7(1):e2352094. doi:10.1001/jamanetworkopen.2023.52094

461. Angermann CE, Gelbrich G, Sto¨rk S, et al. Effect of escitalopram on all cause mortality and hospitalization in patients with heart failure and depression: the MOOD-HF Randomized Clinical Trial. JAMA 2016;315:2683–2693.

462. O'Connor CM, Jiang W, Kuchibhatla M, et al. Safety and Efficacy of Sertraline for Depression in Patients With Heart Failure: Results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) Trial. J Am Coll Cardiol 2010;56(9):692-9.

463. Hedrick R, Korouri S, Tadros E, et al. The impact of antidepressants on depressive symptom severity, quality of life, morbidity, and mortality in heart failure: a systematic review. Drugs Context 2020;9:2020-5-4

464. He W, Zhou Y, Ma J, Wei B, Fu Y. Effect of antidepressants on death in patients with heart failure: a systematic review and meta-analysis. Heart Fail Rev 2020;25:919–926.

465. Jeyanantham K, Kotecha D, Thanki D, Dekker R, Lane DA. Effects of cognitive behavioural therapy for depression in heart failure patients: a systematic review and meta-analysis. Heart Fail Rev 2017;22:731–741.

466. Chernoff RA, Messineo G, Kim S, et al. Psychosocial Interventions for Patients With Heart Failure and Their Impact on Depression, Anxiety, Quality of Life, Morbidity, and Mortality: A Systematic Review and Meta-Analysis. Psychosom Med. 2022 Jun 1;84(5):560-580. doi: 10.1097/PSY.0000000000001073.

467. Tu R-H, Zeng Z-Y, Zhong G-Q, et al. Effects of exercise training on depression in patients with heart failure: a systematic review and meta-analysis of randomized controlled trials. Eur J Heart Fail 2014;16:749–757

468. Das A, Roy B, Schwarzer G, et al. Comparison of treatment options for depression in heart failure: A network meta-analysis. J Psychiatr Res. 2019;108:7-23.

469. Blumenthal JA, Babyak MA, O’Connor C, et al. Effects of Exercise Training on Depressive Symptoms in Patients With Chronic Heart Failure: The HF-ACTION Randomized Trial. JAMA. 2012;308(5):465-474.

470. Suzuki T, Shiga T, Kuwahara K, et al. Impact of clustered depression and anxiety on mortality and rehospitalization in patients with heart failure. J Cardiol. 2014;64(6):456-62.

471. Alhurani AS, Dekker RL, Abed MA, et al. The Association of Co-morbid Symptoms of Depression and Anxiety With All-Cause Mortality and Cardiac Rehospitalization in Patients With Heart Failure. Psychosomatics. 2015;56:371-380.

472. Sato Y, Yoshihisa A, Hotsuki Y, et al. Associations of Benzodiazepine With Adverse Prognosis in Heart Failure Patients With Insomnia. Journal of the American Heart Association. 2020;7:e013982.

473. Chuang C, Hsiao FC, Cheng YW, et al. Benzodiazepines in Patients with Heart Failure and Reduced Ejection Fraction. Acta Cardiol Sin. 2022;38(5):573-583.

474. Zwas DR, Keren A, Amir O, Gotsman I. Treatment of Heart Failure Patients with Anxiolytics Is Associated with Adverse Outcomes, with and without Depression. J Clin Med. 2020 Dec 7;9(12):3967. doi: 10.3390/jcm9123967.

475. Ribeirinho-Soares P, Madureira S, Elias C, et al. Benzodiazepine use and mortality in chronic heart failure. Pol Arch Intern Med. 2023; 133: 16464.

476. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599–726.